Delivery Order 75F40119D10024-75F40120F19002
Award Date 9/29/20
Potential Completion Date 9/28/22
Potential Value $1.6M
Federal Agency
Ultimate Awardee
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92111, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $4,130 firm-fixed-price purchase order contract awarded by the National Institute of Neurological Disorders and Stroke (NINDS), a civilian agency, to Pharmaron (Exton) Lab Services LLC, doing business as Absorption Systems. The contract is for an in-vivo pharmacokinetic (PK) study to determine the optimal formulation for dosing cytochrome P inhibitors and analyzing their concentrations in mouse plasma. This contract is not designated as a small business set-aside. Pharmaron is a global...
- This is a firm fixed-price purchase order issued by the National Institute of Diabetes and Digestive and Kidney Diseases, part of the U.S. Department of Health and Human Services, to Pharmaron (Exton) Lab Services LLC, doing business as Absorption Systems, a global life science contract research organization. The $6,800 contract is for testing services related to COVID-19 treatments, as well as pharmacokinetic studies in animals and in vitro transporter studies for novel drug compounds....
- This is a new task order awarded under an existing Indefinite Delivery Indefinite Quantity (IDIQ) contract (HHSF223201610004I) with the Department of Health and Human Services Food and Drug Administration (FDA). The task order, valued at $2,470,791.00, is for a Pharmacokinetic (PK) study of opioid drug products following oral ingestion of chewed products. The study falls under the FDA's In Vivo Study of Generic Drug Products in Human Subjects program. The contract is a Firm Fixed Price...
- This is a $281,500.00 Firm Fixed Price contract awarded by the Food and Drug Administration (FDA) to Physical Pharmaceutica LLC, a for-profit limited liability company, for the investigation of release rates and factors affecting release rate tests of cyclosporine from ophthalmic emulsions using pulsatile microdialysis. The contract has an ultimate completion date of January 15, 2018 and does not have a set-aside designation. The contract is part of the FDA's broader program focused on the...
- This is a firm fixed-price delivery order award to Pharmaron, Inc., a global contract research organization (CRO) specializing in preclinical research services for pharmaceutical and biotechnology companies, as well as government agencies. The $9,180 award was issued by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH). The work will be performed in Louisville, KY and is related to the NIH Bioanalysis Testing Services 2015-2020...
- The Food and Drug Administration (FDA) awarded a delivery order valued at $300,000 to We Pharma, Inc., doing business as WEP Clinical, for the provision of pharmaceutical drug products to support FDA research studies. The contract, which is firm fixed price with no set-aside designation, carries an ultimate completion date of September 16, 2026, and will be performed at the FDA's Takoma Park, Maryland location. We Pharma, a self-certified small disadvantaged business and limited liability...
- This federal contract award was made by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The $101,372.00 firm fixed-price delivery order contract is part of the NIH Bioanalysis Testing Services 2015-2020 indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. Under this award, Pharmaron will provide a range of preclinical research services to support NIDA's drug discovery and development initiatives,...
- This firm fixed-price purchase order contract, valued at $54,000.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health (NIH), to Pharmaron, Inc. Pharmaron is a minority-owned, for-profit Subcontinent Asian (Asian-Indian) American contract research organization that specializes in preclinical drug discovery and development services. The contract is for testing 20 small molecule compounds in rat pharmacokinetic...
- This firm fixed-price purchase order contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Heart, Lung, and Blood Institute to Pharmaron, Inc., a minority-owned for-profit contract research organization, to conduct Good Laboratory Practice (GLP) toxicity studies in rats and dogs. The $102,250.00 contract supports the Institute's Investigational New Drug (IND) enablement project, with Pharmaron performing services such as...
- This is a firm fixed-price purchase order award from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Pharmaron, Inc. The $78,300.00 contract is for testing compounds to evaluate their ability to block cardiac ion channels, which is relevant to drug discovery and development. Pharmaron is a global contract research organization (CRO) that specializes in preclinical research services, including pharmacokinetics,...